- Home
- MNMD
as 03-28-2025 4:00pm EST
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 559.5M | IPO Year: | N/A |
| Target Price: | $25.75 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.03 - $12.22 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mind Medicine (MindMed) Inc. (MNMD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sullivan Mark | MNMD | Chief Legal Officer | Mar 25 '25 | Sell | $6.74 | 6,576 | $44,322.24 | 316,621 | |
| Karlin Dan | MNMD | Chief Medical Officer | Mar 25 '25 | Sell | $6.74 | 6,836 | $46,074.64 | 446,177 | |
| Liao Carrie | MNMD | Chief Accounting Officer | Mar 25 '25 | Sell | $6.74 | 2,347 | $15,818.78 | 144,923 |
Latest Mind Medicine (MindMed) Inc. News
MNMD Breaking Stock News: Dive into MNMD Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
MindMed Announces New Employee Inducement Grants
TipRanks
8 days ago
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
TipRanks
9 days ago
Psychedelic: atai Life Sciences, NRx report quarterly results
Business Wire
13 days ago
MindMed Appoints Matt Wiley as Chief Commercial Officer
TipRanks
16 days ago
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
Business Wire
24 days ago
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
Business Wire
a month ago
MindMed to Present at Leerink’s Global Healthcare Conference 2025
TipRanks
a month ago
Psychedelic: GH Research, Compass Pathways report earnings results
Compare MNMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNMD Mind Medicine (MindMed) Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.